title: Combination of imatinib and established antileukemic treatment modalities for otherwise refractory BCR-ABL positive lymphoblastic leukemia.
authors.affiliation: Department ofInternal Medicine V, University of Heidelberg, Germany. stefan_fruehauf@med.uni-heidelberg.de
authors.forename: Stefan
authors.initials: S
authors.lastname: Fruehauf
authors.forename: Julian
authors.initials: J
authors.lastname: Topaly
authors.forename: Eike C
authors.initials: EC
authors.lastname: Buss
authors.forename: Moritz
authors.initials: M
authors.lastname: Schad
authors.forename: Martin
authors.initials: M
authors.lastname: Goerner
authors.forename: W Jens
authors.initials: WJ
authors.lastname: Zeller
authors.forename: Anthony D
authors.initials: AD
authors.lastname: Ho
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001549:Benzamides; D003131:Combined Modality Therapy; D016044:Fusion Proteins, bcr-abl; D006801:Humans; D000068877:Imatinib Mesylate; D036102:Peripheral Blood Stem Cell Transplantation / Q000379:methods; D010879:Piperazines / Q000008:administration & dosage*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy*; D011743:Pyrimidines / Q000008:administration & dosage*; D018714:Radiotherapy, Adjuvant; D012074:Remission Induction / Q000379:methods; D016879:Salvage Therapy; D019172:Transplantation Conditioning / Q000379:methods
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl